Ni Fan1, Minling Zhang1, Ke Xu2, Xiaoyin Ke3, Yi Ding1, Daping Wang1, Yuping Liu1, Yuping Ning1, Xuefeng Deng4, Hongbo He5. 1. Guangzhou Huiai Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China. 2. Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510, USA. 3. Guangzhou Huiai Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China; Shenzhen Mental Health Center, 1080 Cuizhu Rd., Luohu District, Shenzhen, Guangdong 518020, China. 4. Guangzhou Baiyun Voluntary Drug Rehabilitation Hospital, 586 North of Baiyun Road, Baiyun District, Guangzhou, Guangdong 510440, China. 5. Guangzhou Huiai Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China. Electronic address: vglut2@126.com.
Abstract
AIMS: To evaluate the serum level of vascular endothelial growth factor (VEGF) in a group of chronic ketamine abusers in comparison to healthy controls. METHODS: Eighty-one ketamine abusers who were hospitalized for the treatment of ketamine dependence and 39 healthy controls were recruited. Serum VEGF level was measured by enzyme linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). RESULTS: Serum level of VEGF was significantly lower in chronic ketamine abusers compared to healthy controls (64.6±42.1 vs. 92.4±59.4pg/ml, F=7.243, p=0.008). CONCLUSIONS: Serum level of VEGF decreased in chronic ketamine abusers compared to healthy controls.
AIMS: To evaluate the serum level of vascular endothelial growth factor (VEGF) in a group of chronic ketamine abusers in comparison to healthy controls. METHODS: Eighty-one ketamine abusers who were hospitalized for the treatment of ketamine dependence and 39 healthy controls were recruited. Serum VEGF level was measured by enzyme linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). RESULTS: Serum level of VEGF was significantly lower in chronic ketamine abusers compared to healthy controls (64.6±42.1 vs. 92.4±59.4pg/ml, F=7.243, p=0.008). CONCLUSIONS: Serum level of VEGF decreased in chronic ketamine abusers compared to healthy controls.
Authors: Alberto R Cervantes-Villagrana; Jonathan Garcia-Román; Claudia González-Espinosa; Monica Lamas Journal: Curr Eye Res Date: 2010-08 Impact factor: 2.424
Authors: J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney Journal: Arch Gen Psychiatry Date: 1994-03